Seoul Viosys서울바이오시스
092190 · KOSDAQ · ₩092190 · 서울바이오시스
₩8,580▲ ₩1,980 (30.00%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩764B | ₩699B | ₩504B | ₩439B | ₩489B |
| Cost of sales | ₩653B | ₩596B | ₩481B | ₩420B | ₩407B |
| Gross profit | ₩111B | ₩103B | ₩23B | ₩19B | ₩81B |
| Operating income | ₩226M | ₩3.5B | −₩73B | −₩62B | ₩22B |
| Net income | −₩14B | ₩18B | −₩102B | −₩94B | ₩21B |
| Net income to shareholders | −₩15B | ₩7.1B | −₩89B | −₩86B | ₩4.4B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩718B | ₩796B | ₩733B | ₩756B | ₩776B |
| Current assets | ₩260B | ₩276B | ₩212B | ₩219B | ₩219B |
| Cash and equivalents | ₩14B | ₩9.4B | ₩19B | ₩12B | ₩9.8B |
| Total liabilities | ₩548B | ₩662B | ₩640B | ₩588B | ₩518B |
| Current liabilities | ₩483B | ₩523B | ₩469B | ₩299B | ₩269B |
| Borrowings | ₩206B | ₩316B | ₩336B | ₩329B | ₩320B |
| Total equity | ₩170B | ₩134B | ₩93B | ₩168B | ₩257B |
| Shareholders' equity | ₩78B | ₩39B | ₩18B | ₩79B | ₩165B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩80B | ₩95B | ₩64B | ₩66B | ₩27B |
| Capital spending | ₩55B | ₩67B | ₩73B | ₩60B | ₩136B |
| Free cash flow | ₩26B | ₩28B | −₩9.3B | ₩5.6B | −₩109B |
| Dividends paid | — | — | — | ₩2.2B | ₩5.5B |
Consolidated where available. Amounts in won.
Also known as: Seoul Viosys / 서울바이오시스 / 092190 / KRX:092190
Source: KRX statistical information